- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
AlphaRx Inc. , a specialty pharmaceutical company dedicated to developing the next generation of therapeutic products using nanotechnology, today announced that its Antituberculosis product candidate, Streptomycin nanoparticles, will be the subject of a slide presentation under the title "Advances in Treatment and Pathogenesis of Mycobacterial Infections" at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) to be held September 17-20, 2007 in Chicago. More than 12,000 physicians, researchers and other healthcare professionals from around the globe gather each year at ICAAC to foster worldwide solutions to the problem of infectious diseases.
Dr. Joseph Schwarz, Chief Scientist of AlphaRx is scheduled to present "Effective Treatment of Tuberculosis in Mice with Nanoparticulated Streptomycin." The presentation will elucidate that Streptomycin in the Company's nanoparticulated delivery platform, demonstrated increased efficacy and is effectively a cure of model tuberculosis at a dosage 80% lower than that of free drug, provided 100% survival in experimental TB mice model and exhibited noticeable sustained release and targeting of the incorporated drug.
For more information on AlphaRx visit, http://www.Alpharx.com . For more information on the ICAAC 47th annual meeting, scheduled for September 17-20, 2007, visit http://www.icaac.org .
About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company also discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and neurodegenerative diseases.
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.
For more information, please click here
168 Konrad Crescent
Suite 200, Markham
Ontario, Canada L3R 9T9
Director, Market & Business Development
Copyright © AlphaRx Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Yale researchersí technology turns wasted heat into power June 27th, 2016
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Novel gene therapy shows potential for lung repair in asthma May 18th, 2016